<DOC>
	<DOCNO>NCT02245087</DOCNO>
	<brief_summary>The purpose study determine whether pharmacologic lower low density lipoprotein cholesterol ( LDL ) , initiate healthy young middle age adult eliminate markedly reduce composite endpoint incident cause mortality , myocardial infarction , stroke coronary revascularization .</brief_summary>
	<brief_title>Eliminate Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Men 3550 year age Women 45 59 year age ( must sterile &gt; 2 year postmenopausal ) LDL cholesterol great 1.8 mmol/L ( 70 mg/dL ) base test perform within 1 year One risk factor Coronary Heart Disease lipid abnormality : Obesity hypertension [ BP &gt; 140 mmHg systolic waist circumference &gt; 100 cm men &gt; 90 cm woman ] family history premature myocardial infarction [ &lt; 60 year ] South Asian ethnic history currently smoke Currently take cholesterol lower medication Qualify cholesterol lower medication base current guideline Significant renal dysfunction ( creatinine clearance &lt; 30 ml/min ) Significant hepatic dysfunction ( AST/ALT &gt; 2.0 time upper limit normal ) Active malignancy Diabetes Progressive terminal illness , condition subject unlikely survive study period Known allergy , hypersensitivity ( anaphylaxis ) ar adverse reaction statin Participation clinical trial ( except observational study ) within previous 30 day Received investigation product within 30 day prior participation clinical trial Previously enrol clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>atorvastatin</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>stroke</keyword>
	<keyword>revascularization</keyword>
</DOC>